RECENT NEWS

The Government has announced its intention to amend the Medical Devices Regulations 2002 for Great Britain to incorporate EU Common Specifications for high-risk in vitro diagnostic (IVD) devices and to repeal regulations on Coronavirus Test Device Approvals (CTDA).

Randox has launched its new Evidence RABTA (Random Access Biochip Technology Analyser), which the firm says sets a new standard in laboratory diagnostics.

Aiforia Technologies has established a subsidiary in France to strengthen its local presence and to support its growing business in the country.

Artificial intelligence and digital pathology firm PathAI has unveiled the launch of the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories, which aims to platform expands access to latest AI products, unlock real-world data value, and fuel collaborative research with biopharma across a broad network.

Pathologists' examinations of tissue samples from skin cancer tumours improved when they were assisted by an AI tool. The assessments became more consistent and patients' prognoses were described more accurately, details a new study.

Researchers have discovered a strategy to neutralise two highly lethal henipaviruses for which there is currently no approved vaccine or cure.

Lunit, a provider of AI for cancer diagnostics and therapeutics, has announced a new collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions.

Becton Dickinson (BD) has named Bilal Muhsin as Executive Vice President and President of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy.

A major report launched from the Women’s Cancer Screening Taskforce has issued a clear call to Government and NHS leaders: prioritise investment in the workforce behind breast and cervical cancer screening to deliver earlier diagnoses and improve outcomes for women across the UK.

Bio-Rad Laboratories has announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum ddPCR system (pictured) along with the QX700 series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.

Following the publication of the Government’s long-awaited 10 Year Plan for the future of the National Health Service, professional and industry bodies have been responding.

A new ‘innovator passport’ - to be introduced over the next two years - will allow new technology that has been robustly assessed by one NHS organisation to be easily rolled out to others.

NHS patients will be treated and cared for closer to their home by new teams of health professionals, as Prime Minister Keir Starmer revealed the long-awaited 10 Year Plan. The government describes the change as a “brand-new era for the NHS” promising to deliver one of the most seismic shifts in care in the history of the health service.

The pioneering Yellow Card Biobank, launched by the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, is investigating whether the risk of acute pancreatitis from GLP-1 injections for weight loss and type 2 diabetes may be influenced by a person’s genes.

Diatron has launched its new clinical chemistry analyser, the P780. The system is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.

Cell biologists have made a significant advance, uncovering the key role of an enzyme in determining the physical structure and behaviour of cancer cells, including how they spread.

The Institute of Biomedical Science (IBMS) has welcomed the publication of the new Industrial Strategy and its focus on life sciences.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its Business Plan for 2025–26, the final year covered by its 2023-2026 Corporate Plan.

Digital pathology and AI firm PathAI has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for AISight Dx - its digital pathology image management system - for use in primary diagnosis in clinical settings.

Evident has announced the launch of the SLIDEVIEW DX VS200 universal whole-slide imaging scanner, a CE-marked device under the EU IVDR for use in clinical diagnostics in Europe.